During Q3, Bionano Genomics's (NASDAQ:BNGO) reported sales totaled $2.20 million. Despite a 37.55% in earnings, the company posted a loss of $10.23 million. Bionano Genomics collected $1.18 million in revenue during Q2, but reported earnings showed a $7.43 million loss.
What Is ROCE?
Changes in earnings and sales indicate shifts in Bionano Genomics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Bionano Genomics posted an ROCE of -0.7%.
It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future.
Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.
For Bionano Genomics, the return on capital employed ratio shows the current amount of assets may not actually be helping the company achieve higher returns, a note many investors will take into account when making long-term financial decisions.
Q3 Earnings Recap
Bionano Genomics reported Q3 earnings per share at $-0.08/share, which did not meet analyst predictions of $-0.05/share.
在第三季度,Bionano基因公司(纳斯达克市场代码:BNGO)报告的总销售额为220万美元。尽管该公司盈利37.55%,但仍亏损1,023万美元。生物纳米基因组公司第二季度营收为118万美元,但公布的收益显示亏损743万美元。
什么是ROCE?
收益和销售额的变化表明Bionano Genonomy的已用资本回报率发生了变化,这是一种衡量年度税前利润相对于企业所用资本的指标。一般来说,较高的净资产收益率意味着公司的成功增长,也是未来每股收益较高的迹象。在第三季度,Bionano基因组公司公布的净资产收益率为-0.7%。
重要的是要记住,ROCE评估的是过去的绩效,而不是用作预测工具。这是衡量一家公司近期表现的一个很好的指标,但有几个因素可能会在不久的将来影响收益和销售额。
资本回报率是衡量效率的重要指标,也是比较同行业公司的有用工具。相对较高的ROCE表明,一家公司可能正在产生利润,这些利润可以再投资于更多资本,从而为股东带来更高的回报和不断增长的每股收益。
对于Bionano Genonomy来说,资本回报率表明,目前的资产规模实际上可能并没有帮助公司实现更高的回报,许多投资者在做出长期财务决策时会考虑这一点。
第三季度收益摘要
BioNano Genology公布第三季度每股收益为-0.08美元,低于分析师预测的-0.05美元。